Cargando…
Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care
BACKGROUND: Newly approved, drug-modifying therapies are associated with still unknown adverse events, although clinical trials leading to approval have strict inclusion and exclusion criteria and analyse safety and efficacy. OBJECTIVES: The aim of this study was to analyse the eligibility of multip...
Autores principales: | Jalusic, Kris Oliver, Ellenberger, David, Rommer, Paulus, Stahmann, Alexander, Zettl, Uwe, Berger, Klaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521377/ https://www.ncbi.nlm.nih.gov/pubmed/33467978 http://dx.doi.org/10.1177/1352458520985118 |
Ejemplares similares
-
Epileptic seizures at multiple sclerosis onset and their role in disease progression
por: Grothe, Matthias, et al.
Publicado: (2023) -
Management of MS Patients Treated With Daclizumab – a Case Series of 267 Patients
por: Rommer, Paulus S., et al.
Publicado: (2020) -
Aggressive multiple sclerosis: a matter of measurement and timing
por: Ellenberger, David, et al.
Publicado: (2020) -
Treatment patterns in pediatric patients with multiple sclerosis in Germany—a nationwide claim-based analysis
por: Frahm, Niklas, et al.
Publicado: (2021) -
Relapsing and progressive MS: the sex-specific
perspective
por: Rommer, Paulus Stefan, et al.
Publicado: (2020)